Insights

Should you buy these beaten down ASX 200 shares?

Should you buy the beaten down shares of Altium Limited (ASX:ALU) and CSL Limited (ASX:CSL) right now? I think you should…
The post Should you buy these beaten down ASX 200 shares? appeared first on Motley Fool Australia. –

Question mark made up of banknotes in front of blue background

The recent market volatility has been very disappointing and weighed heavily on a number of ASX shares.

One positive is that I believe it has dragged the shares of some quality companies down to very attractive levels.

Two beaten down ASX 200 shares that I would buy are listed below. Here’s why I think they could be good value:

Altium Limited (ASX: ALU)

The Altium share price has been caught up in the tech selloff and is down 22% from its high. While this is disappointing for shareholders, I believe it is a buying opportunity for non-shareholders. This is because I’m confident that this electronic design software company has an exceptionally bright future ahead of it.

The key product in its portfolio is Altium Designer, which has exposure to the rapidly growing Internet of Things and artificial intelligence markets. These two markets are underpinning the proliferation of electronic devices globally and look set to drive strong demand for Altium Designer and its newly released cloud-based Altium 365 offering over the coming years. Management is aiming to grow its revenue to US$500 million by 2025-2026. This compares to revenue of US$189 million in FY 2020. Due to the quality of its offering and favourable industry tailwinds, I’m very confident it will get there.

CSL Limited (ASX: CSL)

The CSL share price has fallen just under 18% from its 52-week high. I think this is a buying opportunity for investors that are looking for long term options. This is because I believe the biotherapeutics giant is perfectly positioned to deliver consistently solid earnings growth over the next decade thanks to its CSL Behring and Seqirus businesses.

CSL Behring is the global leader in plasma therapies and the name behind immunoglobulins products such as Privgen and Hizentra. It also owns haemophilia products Idelvion and Afstyla, among others. The Seqirus business is the second-largest player in the influenza vaccines industry. It plans to manufacture COVID-19 vaccines for Australia should they be successfully developed. Both businesses are also investing heavily in research and development activities and have a large number of potentially lucrative therapies and vaccines at various stages of development.

These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Altium. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Should you buy these beaten down ASX 200 shares? appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!